Assertio Holdings, Inc. (ASRT)

US — Healthcare Sector
Peers: AGRX  AMRX  ACRX  LFCR  IRWD  NBIX  DCPH  ESPR  ANIP  ALKS  RDY  COLL  PCRX  ITCI  CTLT  AMPH  ALVO  EGRX  EOLS 

Automate Your Wheel Strategy on ASRT

With Tiblio's Option Bot, you can configure your own wheel strategy including ASRT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol ASRT
  • Rev/Share 1.2438
  • Book/Share 1.1343
  • PB 0.5981
  • Debt/Equity 0.3587
  • CurrentRatio 1.6576
  • ROIC -0.2095

 

  • MktCap 64987205.0
  • FreeCF/Share 0.0665
  • PFCF 10.2149
  • PE -2.1551
  • Debt/Assets 0.1359
  • DivYield 0
  • ROE -0.2448

 

  • Rating
  • Score
  • Recommendation
  • P/E Score
  • DCF Score
  • P/B Score
  • D/E Score

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Assertio Holdings, Inc. (NASDAQ: ASRT); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel
ASRT
Published: February 12, 2025 by: GlobeNewsWire
Sentiment: Neutral

CHICAGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed in Lake County Circuit Court, Nineteenth Judicial Circuit, State of Illinois, on behalf of all persons and entities who acquired Assertio Holdings, Inc. (NASDAQ: ASRT) (“Assertio” or the “Company”) common stock issued in exchange for Spectrum Pharmaceuticals, Inc. (“Spectrum”) common stock in connection with Assertio's July 31, 2023 merger with Spectrum (the “Merger”), charging the Company and certain of its current and former senior executives and directors with violations of the federal securities laws (collectively, “Defendants”).

Read More
image for news INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Assertio Holdings, Inc. (NASDAQ: ASRT); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel

About Assertio Holdings, Inc. (ASRT)

  • IPO Date 1997-12-03
  • Website https://www.assertiotx.com
  • Industry Drug Manufacturers - Specialty & Generic
  • CEO Mr. Brendan P. O'Grady
  • Employees 58
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.